GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (WBO:NNO2) » Definitions » Common Stock

Novo Nordisk AS (WBO:NNO2) Common Stock : €60 Mil (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Novo Nordisk AS Common Stock?

Novo Nordisk AS's quarterly common stock declined from Mar. 2024 (€60 Mil) to Jun. 2024 (€60 Mil) but then increased from Jun. 2024 (€60 Mil) to Sep. 2024 (€60 Mil).

Novo Nordisk AS's annual common stock declined from Dec. 2021 (€62 Mil) to Dec. 2022 (€61 Mil) and declined from Dec. 2022 (€61 Mil) to Dec. 2023 (€61 Mil).


Novo Nordisk AS Common Stock Historical Data

The historical data trend for Novo Nordisk AS's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Common Stock Chart

Novo Nordisk AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.26 63.18 62.13 61.29 60.51

Novo Nordisk AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.48 60.51 60.49 59.76 59.82

Novo Nordisk AS Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Novo Nordisk AS Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines